Characteristics of TRK-130 (Naltalimide), a Novel Opioid Ligand, as a New Therapeutic Agent for Overactive Bladder

Morihiro Fujimura; Naoki Izumimoto; Shinobu Momen; Satoru Yoshikawa; Ryosuke Kobayashi; Sayoko Kanie; Mikito Hirakata; Toshikazu Komagata; Satoshi Okanishi; Tadatoshi Hashimoto; Naoki Yoshimura; Koji Kawai

doi:10.1124/jpet.114.214031

Research ArticleGastrointestinal, Hepatic, Pulmonary, and Renal

Characteristics of TRK-130 (Naltalimide), a Novel Opioid Ligand, as a New Therapeutic Agent for Overactive Bladder

Morihiro Fujimura, Naoki Izumimoto, Shinobu Momen, Satoru Yoshikawa, Ryosuke Kobayashi, Sayoko Kanie, Mikito Hirakata, Toshikazu Komagata, Satoshi Okanishi, Tadatoshi Hashimoto, Naoki Yoshimura and Koji Kawai

Journal of Pharmacology and Experimental Therapeutics September 2014, 350 (3) 543-551; DOI: https://doi.org/10.1124/jpet.114.214031

Morihiro Fujimura

Pharmaceutical Research Laboratories, Toray Industries, Inc., Kanagawa, Japan (M.F., N.I., S.M., S.Y., R.K., S.K., M.H., T.K., K.K.); Pharmaceutical Research Division, Takeda Pharmaceutical Co. Ltd., Kanagawa, Japan (S.O., T.H.); and Departments of Urology and Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania (N.Y.)

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Naoki Izumimoto

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Shinobu Momen

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Satoru Yoshikawa

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Ryosuke Kobayashi

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sayoko Kanie

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mikito Hirakata

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Toshikazu Komagata

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Satoshi Okanishi

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Tadatoshi Hashimoto

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Naoki Yoshimura

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Koji Kawai

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
eLetters
PDF

JPET articles become freely available 12 months after publication, and remain freely available for 5 years.

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.

Click here for information on institutional subscriptions.
Click here for information on individual ASPET membership.

Log in using your username and password

Username *

Password *

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

PreviousNext

In this issue

Journal of Pharmacology and Experimental Therapeutics

Vol. 350, Issue 3

1 Sep 2014

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Editorial Board (PDF)
Front Matter (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Characteristics of TRK-130 (Naltalimide), a Novel Opioid Ligand, as a New Therapeutic Agent for Overactive Bladder

Message Subject (Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics

Message Body (Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Citation Tools

Research ArticleGastrointestinal, Hepatic, Pulmonary, and Renal

A New Drug Candidate for Overactive Bladder

Journal of Pharmacology and Experimental Therapeutics September 1, 2014, 350 (3) 543-551; DOI: https://doi.org/10.1124/jpet.114.214031

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Research ArticleGastrointestinal, Hepatic, Pulmonary, and Renal

A New Drug Candidate for Overactive Bladder

Journal of Pharmacology and Experimental Therapeutics September 1, 2014, 350 (3) 543-551; DOI: https://doi.org/10.1124/jpet.114.214031

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Jump to section

Article
Figures & Data
Info & Metrics
eLetters
PDF

Main menu

User menu

Search

Characteristics of TRK-130 (Naltalimide), a Novel Opioid Ligand, as a New Therapeutic Agent for Overactive Bladder

JPET articles become freely available 12 months after publication, and remain freely available for 5 years.

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.

Purchase access

In this issue

A New Drug Candidate for Overactive Bladder

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Navigate

More Information

ASPET's Other Journals